. Author manuscript; available in PMC: 2023 Jul 19.

Published in final edited form as: Diabetologia. 2022 Oct 6;66(1):163–173. doi: 10.1007/s00125-022-05804-4

Table 3.

Outcomes per recipient of immunosuppression-related SAEs and procedure-related SAEs for the 4CFF vs the <4CFF subgroups

Outcome	Immunosuppression-related SAE		Product/infusion procedure-related SAE

	4CFF (N=126)	<4CFF (N=272)	4CFF (N=126)	<4CFF (N=272)

No SAE	67 (53.2)	180 (66.2)	88 (69.8)	200 (73.5)
Recovered	53 (42.1)	77 (28.3)	37 (29.4)	70 (25.7)
Sequelae	6 (4.8)	11 (4.0)	1 (0.8)	2 (0.7)
Disability	0 (0)	2 (0.7)	0 (0)	0 (0)
Death	0 (0)	2 (0.7)	0 (0)	0 (0)

Data are presented as n (%)